Newly developed retatrutide, a twin -action treatment targeting simultaneously GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Initial clinical studies have revealed significant decreases in physical size and gains in metabolic markers for individuals with excess weight . Scientists believe this unique appro